RxDoctor Payments Data

Payal Desai, MD

Hematology · Charlotte, NCNPI 1629109285

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Chiesi USA, Inc. at 26.0% of the total. Reporting peaked in 2023 at $10,882 and has fallen 72.1% since, to $3,033 in 2025.

$39,003in general payments, 2019–2025

Across 48 payments — averaging $812.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chiesi USA, Inc.$10K
  • Global Blood Therapeutics, Inc.$6K
  • Vertex$6K
  • National Marrow Donor Program$6K
  • Pfizer$5K
  • Acelrx Pharmaceuticals, Inc.$2K
  • plus $5K from 7 others
$917,309in research payments, 2019–2025

Across 133 payments — averaging $6897.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$455K
  • Global Blood Therapeutics, Inc.$201K
  • Pfizer$102K
  • CSL Behring$66K
  • Takeda Pharmaceuticals U.S.A., Inc.$56K
  • Shire North American Group Inc$22K
  • plus $14K from 2 others

What the payments were for

  • Consulting fees$20,12252%
  • Speaking & faculty fees$11,90531%
  • Travel & lodging$5,33814%
  • Food & beverage$1,6374%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,003 in reported general payments places this provider in the 70th percentile of 65 hematology providers in North Carolina.

See all hematology providers in North Carolina

Medicare billing

Part B allowed, 2024
$6,543
Medicare patients
29
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxbrytaVoxelotor30$360,762
Ferriprox (2 Times A Day)Deferiprone13$252,988
EndariGlutamine46$165,588
XareltoRivaroxaban32$17,966
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl58$12,406
EliquisApixaban12$9,480
Deferasirox27$6,600
Hydroxyurea131$2,904
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen43$691
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$494
Oxycodone Hcl52$464
Gabapentin52$357
Duloxetine Hcl26$209
Ondansetron Hcl17$153
Omeprazole32$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Global Blood Therapeutics, Inc.Oxbryta$6,184$360,76230 claims
Chiesi USA, Inc.Ferriprox (2 Times A Day)$10,129$252,98813 claims
Emmaus Medical, Inc.Endari$338$165,58846 claims
PfizerEliquis$4,606$9,48012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 65 hematology providers in North Carolina.

Other hematology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →